Eli Lilly and Company has taken the lead in in the development and tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant potential to improve glycemic control and reduce cardiovascular risks. The complex manufacturing process of tirzepatide involves a series of precision